SEARCH OUR PRODUCT CATALOG

FISH Probe Products & Services
Request More Information

TRIM24-BRAF Fusion FISH Probe

The TRIM24-BRAF Fusion FISH Probe is used to confirm a fusion of the TRIM24 and BRAF genes. The fusion of the TRIM24 and BRAF genes has been associated with Liver Hepatocellular Carcinoma, and Rectum Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping
Download Datasheet Download FISH Protocol Download Material Safety Data Sheet

SKU Test Kits Buffer Dye Color Order Now
TRIM24-BRAF-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
TRIM24-BRAF-20-RERE 20 (40 μL) 200 μL
TRIM24-BRAF-20-REOR 20 (40 μL) 200 μL
TRIM24-BRAF-20-REGO 20 (40 μL) 200 μL
TRIM24-BRAF-20-REGR 20 (40 μL) 200 μL
TRIM24-BRAF-20-REAQ 20 (40 μL) 200 μL
TRIM24-BRAF-20-ORRE 20 (40 μL) 200 μL
TRIM24-BRAF-20-OROR 20 (40 μL) 200 μL
TRIM24-BRAF-20-ORGO 20 (40 μL) 200 μL
TRIM24-BRAF-20-ORAQ 20 (40 μL) 200 μL
TRIM24-BRAF-20-GORE 20 (40 μL) 200 μL
TRIM24-BRAF-20-GOOR 20 (40 μL) 200 μL
TRIM24-BRAF-20-GOGO 20 (40 μL) 200 μL
TRIM24-BRAF-20-GOGR 20 (40 μL) 200 μL
TRIM24-BRAF-20-GOAQ 20 (40 μL) 200 μL
TRIM24-BRAF-20-GRRE 20 (40 μL) 200 μL
TRIM24-BRAF-20-GROR 20 (40 μL) 200 μL
TRIM24-BRAF-20-GRGO 20 (40 μL) 200 μL
TRIM24-BRAF-20-GRGR 20 (40 μL) 200 μL
TRIM24-BRAF-20-GRAQ 20 (40 μL) 200 μL
TRIM24-BRAF-20-AQRE 20 (40 μL) 200 μL
TRIM24-BRAF-20-AQOR 20 (40 μL) 200 μL
TRIM24-BRAF-20-AQGO 20 (40 μL) 200 μL
TRIM24-BRAF-20-AQGR 20 (40 μL) 200 μL
TRIM24-BRAF-20-AQAQ 20 (40 μL) 200 μL

BRAF Gene Summary

This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]

Gene Name: B-Raf Proto-oncogene, Serine/threonine Kinase

Chromosome: CHR7: 140433812 -140624564

Locus: 7q34

TRIM24 Gene Summary

The protein encoded by this gene mediates transcriptional control by interaction with the activation function 2 (AF2) region of several nuclear receptors, including the estrogen, retinoic acid, and vitamin D3 receptors. The protein localizes to nuclear bodies and is thought to associate with chromatin and heterochromatin-associated factors. The protein is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains - a RING, a B-box type 1 and a B-box type 2 - and a coiled-coil region. Two alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Jul 2008]

Gene Name: Tripartite Motif Containing 24

Chromosome: CHR7: 138145078 -138270332

Locus: 7q33-q34

Gene Diseases

The TRIM24 BRAF Fusion has been associated with the following diseases:

Disease Name
Liver Hepatocellular Carcinoma
Rectum Adenocarcinoma

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms

BRAF rearrangements are found in about 20% of acinar-type neoplasms, and may serve as a potential treatment target. This study examined the efficacy of FISH versus NGS for detecting BRAF translocations in 31 acinar-type neoplasms. As part of FISH analysis, our BRAF break apart probes were used to detect BRAF rearrangements. The team found that, compared to NGS, FISH was highly sensitive, specific, and time- and cost-effective.
Read More

Alternative lengthening of telomeres, ATRX loss and H3_K27M mutations in histologically defined pilocytic astrocytoma with anaplasia

Pilocytic astrocytoma (PA) is a type of brain tumor. Certain molecular abnormalities can be indicative of PA such as alternative lengthening of telomeres or loss of ATRX. In many cases of PA, there is a duplication in the kinase domain of the BRAF gene called KIAA1549_BRAF. Red and green FISH probes were used to identify this BRAF gene duplication. The duplication was found to be present in 31% of the PA patients.
Read More

Atypical Spitzoid Neoplasms in Childhood: A Molecular and Outcome Study

Atypical spitzoid neoplasms (APNs) are primarily pediatric lesions characterized by their intermediate features; clinically and histopathologically, they fall somewhere between benign spitz nevi and malignant melanoma. The genetics of these tumors are still poorly understood. In this study, 34 APNs were analyzed using FISH and IHC. Our ALK, BRAF, and NTRK1 break-apart FISH probes were used to detect rearrangements of the genes .
Read More

Genomic Profiling of Primary Histiocytic Sarcoma Reveals Two Molecular Subgroups

Histiocytic sarcoma (HS) is a rare, aggressive cancer that can occur in the GI tract, skin and liver. This study analyzed 21 cases of HS using RNA sequencing, whole exome sequencing, and FISH. BAC FISH probes from Empire Genomics were used to detect NF1 (RP11-14206) and PTNP11 (RP11-748H13, RP11-9P8, RP11-90F3, RP11-660M3), while BRAF translocations were identified using our BRAF break-apart probe. The team found many abnormalities within the RAS-RAF-MAPK pathway in all 21 cases, with aberrations in NF1 (6/21), MAP2K1 (5/21), PTPN11 (4/21), BRAF (4/21), KRAS (4/21), NRAS (1/21) and LZTR1 (1/21).
Read More